115 related articles for article (PubMed ID: 8897090)
1. Synthesis and conformational analysis of cyclic pentapeptide endothelin antagonists.
Lin M; Chan MF; Balaji VN; Castillo RS; Larive CK
Int J Pept Protein Res; 1996 Sep; 48(3):229-39. PubMed ID: 8897090
[TBL] [Abstract][Full Text] [Related]
2. Rediscovering an endothelin antagonist (BQ-123): a self-deconvoluting cyclic pentapeptide library.
Spatola AF; Crozet Y
J Med Chem; 1996 Sep; 39(19):3842-6. PubMed ID: 8809172
[TBL] [Abstract][Full Text] [Related]
3. A conformational study by 1H NMR of a cyclic pentapeptide antagonist of endothelin.
Coles M; Sowemimo V; Scanlon D; Munro SL; Craik DJ
J Med Chem; 1993 Sep; 36(18):2658-65. PubMed ID: 8410978
[TBL] [Abstract][Full Text] [Related]
4. Conformational study of cyclo[D-Trp-D-Asp-Pro-D-Val-Leu], an endothelin-A receptor-selective antagonist.
Atkinson RA; Pelton JT
FEBS Lett; 1992 Jan; 296(1):1-6. PubMed ID: 1309703
[TBL] [Abstract][Full Text] [Related]
5. Solution conformation of a cyclic pentapeptide endothelin antagonist. Comparison of structures obtained from constrained dynamics and conformational search.
Krystek SR; Bassolino DA; Bruccoleri RE; Hunt JT; Porubcan MA; Wandler CF; Andersen NH
FEBS Lett; 1992 Mar; 299(3):255-61. PubMed ID: 1544503
[TBL] [Abstract][Full Text] [Related]
6. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
[TBL] [Abstract][Full Text] [Related]
7. Multiple solution conformations of the integrin-binding cyclic pentapeptide cyclo(-Ser-D-Leu-Asp-Val-Pro-). Analysis of the (phi, psi) space available to cyclic pentapeptides.
Viles JH; Mitchell JB; Gough SL; Doyle PM; Harris CJ; Sadler PJ; Thornton JM
Eur J Biochem; 1996 Dec; 242(2):352-62. PubMed ID: 8973654
[TBL] [Abstract][Full Text] [Related]
8. Conformations of cyclic pentapeptide endothelin receptor antagonists.
Bean JW; Peishoff CE; Kopple KD
Int J Pept Protein Res; 1994 Sep; 44(3):223-32. PubMed ID: 7822098
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of potent and selective alpha(4)beta(7) integrin antagonists.
Boer J; Gottschling D; Schuster A; Semmrich M; Holzmann B; Kessler H
J Med Chem; 2001 Aug; 44(16):2586-92. PubMed ID: 11472212
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and solution conformation of c(D-Trp-D-Cys(SO3-Na+)-Pro-D-Val-Leu), a potent endothelin-A receptor antagonist.
Bogusky MJ; Brady SF; Sisko JT; Nutt RF; Smith GM
Int J Pept Protein Res; 1993 Aug; 42(2):194-203. PubMed ID: 8407113
[TBL] [Abstract][Full Text] [Related]
11. Cyclic hexapeptide endothelin receptor antagonists highly potent for both receptor subtypes ETA and ETB.
Kikuchi T; Ohtaki T; Kawata A; Imada T; Asami T; Masuda Y; Sugo T; Kusumoto K; Kubo K; Watanabe T
Biochem Biophys Res Commun; 1994 May; 200(3):1708-12. PubMed ID: 8185629
[TBL] [Abstract][Full Text] [Related]
12. Location of alkali metal binding sites in endothelin A selective receptor antagonists, cyclo(D-Trp-D-Asp-Pro-D-Val-Leu) and cyclo(D-Trp-D-Asp-Pro-D-Ile-Leu), from multistep collisionally activated decompositions.
Ngoka LC; Gross ML
J Mass Spectrom; 2000 Feb; 35(2):265-76. PubMed ID: 10679990
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of the unique and potent agouti-related protein (AGRP)-melanocortin chimeric Tyr-c[beta-Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH2 peptide template.
Wilczynski A; Wilson KR; Scott JW; Edison AS; Haskell-Luevano C
J Med Chem; 2005 Apr; 48(8):3060-75. PubMed ID: 15828845
[TBL] [Abstract][Full Text] [Related]
14. Combined use of molecular dynamics simulations and NMR to explore peptide bond isomerization and multiple intramolecular hydrogen-bonding possibilities in a cyclic pentapeptide, cyclo(Gly-Pro-D-Phe-Gly-Val).
Liu ZP; Gierasch LM
Biopolymers; 1992 Dec; 32(12):1727-39. PubMed ID: 1472655
[TBL] [Abstract][Full Text] [Related]
15. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
[TBL] [Abstract][Full Text] [Related]
16. Mimicry of beta II'-turns of proteins in cyclic pentapeptides with one and without D-amino acids.
Weisshoff H; Präsang C; Henklein P; Frömmel C; Zschunke A; Mügge C
Eur J Biochem; 1999 Feb; 259(3):776-88. PubMed ID: 10092864
[TBL] [Abstract][Full Text] [Related]
17. Competitive and non competitive interactions of BQ-123 with endothelin ETA receptors.
Vigne P; Breittmayer JP; Frelin C
Eur J Pharmacol; 1993 May; 245(3):229-32. PubMed ID: 8335061
[TBL] [Abstract][Full Text] [Related]
18. Endothelin (ET)-1-induced inhibition of ATP release from PC-12 cells is mediated by the ETB receptor: differential response to ET-1 on ATP, neuropeptide Y, and dopamine levels.
Gardner A; Westfall TC; Macarthur H
J Pharmacol Exp Ther; 2005 Jun; 313(3):1109-17. PubMed ID: 15687374
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity studies of reduced-size gonadotropin-releasing hormone agonists derived from the sequence of an endothelin antagonist.
Yahalom D; Rahimipour S; Koch Y; Ben-Aroya N; Fridkin M
J Med Chem; 2000 Jul; 43(15):2824-30. PubMed ID: 10956190
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1-evoked calcium transients in UMR-106 osteoblastic osteosarcoma cells are mediated through endothelin-A and endothelin-B receptors.
Semler DE; Ohlstein EH; Nambi P; Slater C; Stern PH
J Pharmacol Exp Ther; 1995 Mar; 272(3):1052-8. PubMed ID: 7891315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
